SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Catalent, Inc. by Novo Holdings
You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Catalent by Novo Holdings (“Novo”).
- You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of Catalent by Novo Holdings (“Novo”).
- As a result of the merger, Catalent stockholders will receive $63.50 per share in cash.
- Novo is affiliated with Novo Nordisk, and Catalent is the main manufacturing partner for Novo Nordisk’s blockbuster weight loss drug, Wegovy.
- Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington, D.C.